JP2023500532A5 - - Google Patents
Info
- Publication number
- JP2023500532A5 JP2023500532A5 JP2022526073A JP2022526073A JP2023500532A5 JP 2023500532 A5 JP2023500532 A5 JP 2023500532A5 JP 2022526073 A JP2022526073 A JP 2022526073A JP 2022526073 A JP2022526073 A JP 2022526073A JP 2023500532 A5 JP2023500532 A5 JP 2023500532A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- stage
- hydroxy
- coupling agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1916210.6 | 2019-11-07 | ||
| GBGB1916210.6A GB201916210D0 (en) | 2019-11-07 | 2019-11-07 | High purity tryptamines and methods of synthesis thereof |
| GBGB1917320.2A GB201917320D0 (en) | 2019-11-28 | 2019-11-28 | Novel compounds |
| GB1917320.2 | 2019-11-28 | ||
| GB2008303.6A GB2585978B (en) | 2019-06-03 | 2020-06-02 | Therapeutic compositions |
| GB2008303.6 | 2020-06-02 | ||
| PCT/EP2020/081503 WO2021089873A1 (en) | 2019-11-07 | 2020-11-09 | Method of synthesis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023500532A JP2023500532A (ja) | 2023-01-06 |
| JP2023500532A5 true JP2023500532A5 (https=) | 2023-02-02 |
| JP7422473B2 JP7422473B2 (ja) | 2024-01-26 |
Family
ID=75849570
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022526073A Active JP7422473B2 (ja) | 2019-11-07 | 2020-11-09 | 合成方法 |
| JP2022526074A Active JP7423131B2 (ja) | 2019-11-07 | 2020-11-09 | 化合物 |
| JP2023202672A Active JP7748437B2 (ja) | 2019-11-07 | 2023-11-30 | 化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022526074A Active JP7423131B2 (ja) | 2019-11-07 | 2020-11-09 | 化合物 |
| JP2023202672A Active JP7748437B2 (ja) | 2019-11-07 | 2023-11-30 | 化合物 |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US11643390B2 (https=) |
| EP (3) | EP3844147B1 (https=) |
| JP (3) | JP7422473B2 (https=) |
| KR (2) | KR20220082092A (https=) |
| CN (2) | CN114829341B (https=) |
| AU (2) | AU2020378647B2 (https=) |
| BR (1) | BR112022008919A2 (https=) |
| CA (2) | CA3160337C (https=) |
| DK (1) | DK3844147T3 (https=) |
| ES (2) | ES2940811T3 (https=) |
| HR (2) | HRP20220797T1 (https=) |
| HU (2) | HUE061482T2 (https=) |
| IL (2) | IL292754B2 (https=) |
| MX (1) | MX2022005399A (https=) |
| NZ (1) | NZ788543A (https=) |
| PL (2) | PL3844147T3 (https=) |
| PT (2) | PT3844147T (https=) |
| WO (2) | WO2021089873A1 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| EP3753923A1 (en) | 2019-06-19 | 2020-12-23 | GH Research Limited | Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent |
| KR20220082092A (ko) | 2019-11-07 | 2022-06-16 | 스몰 파마 엘티디 | 화합물 |
| KR20220137081A (ko) | 2020-02-04 | 2022-10-11 | 마인드셋 파마 인크. | Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체 |
| US11332441B2 (en) * | 2020-03-23 | 2022-05-17 | Caamtech, Inc. | Crystalline N-methyl tryptamine derivatives |
| WO2021226416A1 (en) | 2020-05-08 | 2021-11-11 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| MX2022014900A (es) * | 2020-06-02 | 2023-03-27 | Small Pharma Ltd | Composiciones terapeuticas que comprenden compuestos n,n-dimetiltriptamina deuterada o parcialmente deuterada. |
| EP3902541B1 (en) * | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| BR112022025306A2 (pt) | 2020-06-12 | 2023-02-28 | Beckley Psytech Ltd | Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| US12521370B2 (en) | 2020-12-01 | 2026-01-13 | Cybin Uk Ltd | Inhalable formulations |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| US12534441B2 (en) | 2021-01-15 | 2026-01-27 | Beckley Psytech Limited | Tryptamine analogues |
| EP4155306A1 (en) | 2021-01-15 | 2023-03-29 | Beckley Psytech Limited | Neuroactive ergoline analogue |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| CA3218110A1 (en) | 2021-05-25 | 2022-12-01 | Majed Fawaz | New n,n-dimethyltryptamine salts and crystalline salt forms |
| AU2022287974A1 (en) | 2021-06-09 | 2024-01-04 | Atai Therapeutics, Inc. | Novel prodrugs and conjugates of dimethyltryptamine |
| EP4122916A1 (en) * | 2021-07-22 | 2023-01-25 | GH Research Ireland Limited | Method for preparing an organic compound |
| EP4373807A1 (en) * | 2021-07-22 | 2024-05-29 | GH Research Ireland Limited | Method for preparing a tryptamine derivative |
| US11697638B2 (en) * | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| EP4159192A1 (en) | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders |
| EP4433049A1 (en) | 2021-11-18 | 2024-09-25 | Cybin UK Ltd | Injectable and inhalable formulations |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
| WO2023108174A1 (en) * | 2021-12-10 | 2023-06-15 | Terran Biosciences, Inc. | Analogs of 6-methoxy- n, n-dimethyltryptamine |
| WO2023129956A2 (en) | 2021-12-30 | 2023-07-06 | ATAI Life Sciences AG | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| WO2023147423A1 (en) * | 2022-01-28 | 2023-08-03 | Miralogx Llc | Anxiolytic compounds, pharmaceutical compositions, and methods of treating anxiety and other disorders |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| US20230346718A1 (en) * | 2022-04-27 | 2023-11-02 | Yale University | Method of treating, ameliorating and/or preventing depression |
| US12264131B2 (en) * | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| GB202212116D0 (en) | 2022-08-19 | 2022-10-05 | Beckley Psytech Ltd | Pharmaceutically acceptable salts and Compositions thereof |
| AU2023361184A1 (en) | 2022-10-13 | 2025-04-24 | Cybin Uk Ltd | Method of administration of a parenteral formulation comprising a psychedelic agent |
| WO2024108195A1 (en) | 2022-11-17 | 2024-05-23 | Remedi, Inc. | Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use |
| TW202430149A (zh) * | 2022-12-01 | 2024-08-01 | 美商雅特益醫療公司 | Ｎ，ｎ－二甲基色胺之結晶形式及其使用方法 |
| CN121038789A (zh) | 2023-01-23 | 2025-11-28 | 赛本英国有限公司 | 通过肠胃外施用单一有效肠胃外剂量的短效致幻剂治疗精神或神经障碍 |
| CN121194779A (zh) | 2023-03-31 | 2025-12-23 | 赛本英国有限公司 | 包含单胺抗抑郁剂和短效致幻剂的组合 |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| US12180158B1 (en) * | 2023-08-03 | 2024-12-31 | Gilgamesh Pharmaceuticals, Inc. | Crystalline fumarate salts of n-ethyl-2-(5-fluoro-1H-indol-3-yl)-n-methylethan-1-amine |
| US12129234B1 (en) * | 2023-08-03 | 2024-10-29 | Gilgamesh Pharmaceuticals, Inc. | Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine |
| WO2026013174A1 (en) | 2024-07-10 | 2026-01-15 | Cybin Uk Ltd | Pharmaceutical compositions comprising deuterated n,n-dimethyltryptamine |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4336378A (en) | 1980-04-10 | 1982-06-22 | Sandoz, Inc. | Isoxazolyl indolamines |
| AU1928892A (en) * | 1991-06-21 | 1993-01-25 | Smithkline Beecham Plc | Tryptamine analogues, their synthesis and their use as 5-ht1-like or 5-ht2 receptor agonists |
| US6376531B1 (en) | 1998-11-13 | 2002-04-23 | Rupert Charles Bell | Method of treatment using deuterium compounds |
| EP1292282A2 (en) | 2000-06-16 | 2003-03-19 | RTP Pharma Inc. | Improved injectable dispersions of propofol |
| WO2004085392A1 (en) | 2003-03-25 | 2004-10-07 | Faust Pharmaceuticals | Melatonin derivatives and their use for treating neurological dysfunctions |
| CA2666149A1 (en) | 2006-10-19 | 2008-04-24 | Auspex Pharmaceuticals, Inc. | Substituted indoles |
| WO2008071455A1 (en) | 2006-12-15 | 2008-06-19 | Bayer Schering Pharma Aktiengesellschaft | Bicyclic acyltryptophanols |
| CZ302424B6 (cs) * | 2007-06-13 | 2011-05-11 | Zentiva, A. S. | Zpusob prípravy almotriptanu o vysoké cistote |
| EP3251670A1 (en) * | 2007-08-06 | 2017-12-06 | Biotie Therapies, Inc. | Methods for treating dependence |
| US20090076121A1 (en) | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched sumatriptan |
| EP2209380A4 (en) | 2007-10-09 | 2011-09-14 | Mark T Hamann | METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF |
| US20100113496A1 (en) | 2008-09-25 | 2010-05-06 | Auspex Pharmaceuticals, Inc. | Piperidine modulators of vmat2 |
| EP2771341A4 (en) | 2011-10-28 | 2015-09-23 | Univ Texas | NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER |
| EP4345100A3 (en) | 2012-09-18 | 2024-04-10 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| JP6282721B2 (ja) * | 2013-03-14 | 2018-02-21 | ダート・ニューロサイエンス・（ケイマン）・リミテッド | Ｐｄｅ４阻害剤としての置換ピリジン及びピラジン化合物 |
| AU2015312134A1 (en) | 2014-09-02 | 2017-03-23 | Bhupinder Singh | Deuterated or a non-deuterated molecule and pharmaceutical formulations |
| WO2016181414A1 (en) | 2015-05-12 | 2016-11-17 | Council Of Scientific & Industrial Research | Process for the synthesis of ivacaftor and related compounds |
| EP3519816A4 (en) * | 2016-09-29 | 2020-05-06 | The Regents of the University of California | CONNECTIONS FOR INCREASING NEURONAL PLASTICITY |
| CA3052974A1 (en) | 2017-02-09 | 2018-08-16 | CaaMTech, LLC | Compositions and methods comprising a psilocybin derivative |
| US20200147038A1 (en) | 2017-04-20 | 2020-05-14 | Eleusis Benefit Corporation, Pbc | Assessing and treating psychedelic-responsive subjects |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| MA50786A (fr) * | 2017-10-26 | 2022-04-27 | Blumentech S L | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| WO2019089902A1 (en) | 2017-11-01 | 2019-05-09 | Drexel University | Compounds, compositions, and methods for treating diseases |
| HUE069534T2 (hu) | 2019-02-22 | 2025-03-28 | Gh Res Ireland Limited | 5-Metoxi-N,N-dimetiltriptamint (5-MeO-DMT) tartalmazó készítmény mentális rendellenességek kezelésében történõ alkalmazásra |
| FI4349407T3 (fi) | 2019-02-22 | 2025-06-02 | Gh Res Ireland Limited | 5-metoksi-n,n-dimetyylitryptamiini (5-meo-dmt) vaikean masennuksen hoitoon |
| KR102946120B1 (ko) | 2019-02-27 | 2026-03-30 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클 |
| MX2021010198A (es) * | 2019-02-27 | 2021-09-21 | Univ California | Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales. |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| KR20220082092A (ko) | 2019-11-07 | 2022-06-16 | 스몰 파마 엘티디 | 화합물 |
| CN111072492A (zh) * | 2019-11-29 | 2020-04-28 | 浙江工业大学 | 一种合成3,4-二氯-2-氨基-5-氟联苯的方法 |
| KR20220137081A (ko) | 2020-02-04 | 2022-10-11 | 마인드셋 파마 인크. | Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체 |
| WO2021234608A1 (en) | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| EP3902541B1 (en) | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| GB202008961D0 (en) | 2020-06-12 | 2020-07-29 | Beckley Psytech Ltd | Pharmaceutical composition |
| EP4192451A4 (en) | 2020-08-05 | 2024-08-14 | Universitätsspital Basel | METHOD OF ADMINISTERING INTRAVENOUS DMT FOR DMT-ASSISTED PSYCHOTHERAPY |
| US20220062237A1 (en) | 2020-08-28 | 2022-03-03 | Small Pharma Ltd | Injectable formulation |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| JP7422474B2 (ja) | 2020-08-28 | 2024-01-26 | サイビン ユーケー リミテッド | 注射用製剤 |
| EP4221682A2 (en) | 2020-10-02 | 2023-08-09 | Cybin IRL Limited | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods |
| US11000534B1 (en) | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| US12521370B2 (en) | 2020-12-01 | 2026-01-13 | Cybin Uk Ltd | Inhalable formulations |
| EP4031529B1 (en) | 2020-12-01 | 2023-09-27 | Small Pharma Ltd | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| WO2022117640A1 (en) | 2020-12-01 | 2022-06-09 | Small Pharma Ltd | Inhalable formulations |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
-
2020
- 2020-11-09 KR KR1020227018623A patent/KR20220082092A/ko not_active Ceased
- 2020-11-09 AU AU2020378647A patent/AU2020378647B2/en active Active
- 2020-11-09 BR BR112022008919A patent/BR112022008919A2/pt not_active Application Discontinuation
- 2020-11-09 JP JP2022526073A patent/JP7422473B2/ja active Active
- 2020-11-09 PL PL20816376.6T patent/PL3844147T3/pl unknown
- 2020-11-09 EP EP20816376.6A patent/EP3844147B1/en active Active
- 2020-11-09 IL IL292754A patent/IL292754B2/en unknown
- 2020-11-09 DK DK20816376.6T patent/DK3844147T3/da active
- 2020-11-09 CN CN202080087092.5A patent/CN114829341B/zh active Active
- 2020-11-09 HU HUE20816375A patent/HUE061482T2/hu unknown
- 2020-11-09 PL PL20816375.8T patent/PL3873883T3/pl unknown
- 2020-11-09 HU HUE20816376A patent/HUE059403T2/hu unknown
- 2020-11-09 MX MX2022005399A patent/MX2022005399A/es unknown
- 2020-11-09 AU AU2020381103A patent/AU2020381103B2/en active Active
- 2020-11-09 EP EP20816375.8A patent/EP3873883B1/en active Active
- 2020-11-09 HR HRP20220797TT patent/HRP20220797T1/hr unknown
- 2020-11-09 IL IL292753A patent/IL292753B2/en unknown
- 2020-11-09 PT PT208163766T patent/PT3844147T/pt unknown
- 2020-11-09 CN CN202080087091.0A patent/CN114829340B/zh active Active
- 2020-11-09 PT PT208163758T patent/PT3873883T/pt unknown
- 2020-11-09 CA CA3160337A patent/CA3160337C/en active Active
- 2020-11-09 ES ES20816375T patent/ES2940811T3/es active Active
- 2020-11-09 CA CA3160334A patent/CA3160334C/en active Active
- 2020-11-09 KR KR1020237033500A patent/KR20230142817A/ko not_active Ceased
- 2020-11-09 EP EP22214748.0A patent/EP4180037A1/en active Pending
- 2020-11-09 ES ES20816376T patent/ES2920681T3/es active Active
- 2020-11-09 HR HRP20230281TT patent/HRP20230281T1/hr unknown
- 2020-11-09 NZ NZ788543A patent/NZ788543A/en unknown
- 2020-11-09 WO PCT/EP2020/081503 patent/WO2021089873A1/en not_active Ceased
- 2020-11-09 JP JP2022526074A patent/JP7423131B2/ja active Active
- 2020-11-09 WO PCT/EP2020/081502 patent/WO2021089872A1/en not_active Ceased
-
2021
- 2021-08-26 US US17/412,828 patent/US11643390B2/en active Active
-
2022
- 2022-05-06 US US17/662,261 patent/US11578039B2/en active Active
-
2023
- 2023-01-10 US US18/152,465 patent/US12157723B2/en active Active
- 2023-03-31 US US18/193,866 patent/US12084417B2/en active Active
- 2023-11-30 JP JP2023202672A patent/JP7748437B2/ja active Active
-
2024
- 2024-03-12 US US18/602,171 patent/US20240217929A1/en active Pending
- 2024-10-21 US US18/921,515 patent/US20250042852A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023500532A5 (https=) | ||
| JP7536721B2 (ja) | キナーゼを修飾する１ｈ－ピロロ［２，３－ｂ］ピリジン誘導体の合成 | |
| HRP20230281T1 (hr) | Postupak sinteze | |
| JP3590643B2 (ja) | ７−（置換された）−９−［（置換されたグリシル）アミド］−６−デメチル−６−デオキシテトラサイクリン類の製造方法 | |
| CZ20001613A3 (cs) | Způsob výroby oxazolidinonů | |
| JP7761578B2 (ja) | シクロスポリン誘導体の調製 | |
| JP3204972B2 (ja) | 新規サリドマイド誘導体、その製造方法並びにこれを薬剤として使用する方法 | |
| JP2024524457A5 (https=) | ||
| EP1697313B1 (en) | Processes for the preparation of aminoalkyl phenylcarbamates | |
| JP2011513286A (ja) | コンブレタスタチンの調製方法 | |
| JP2023511152A5 (https=) | ||
| EP2450343A1 (en) | Method for producing threo-3-(3,4-dihydroxyphenyl)-l-serine | |
| JPH06279385A (ja) | Ｎ−（２−ヒドラジノエチル）−ｎ−〔２−（フェニルメトキシ）エチル〕ベンゼンメタンアミン | |
| JP2015526507A (ja) | フルボキサミン遊離塩基の精製方法およびそれを用いた高純度フルボキサミンマレイン酸塩の製造方法 | |
| JPH0350749B2 (https=) | ||
| JP2001261653A5 (https=) | ||
| JP2025506671A5 (https=) | ||
| WO2023058645A1 (ja) | 化合物又はその薬学的に許容される塩の製造方法 | |
| CN104001449B (zh) | 含有联苯基团的季铵盐型Gemini表面活性剂及其制备方法 | |
| JPS5834471B2 (ja) | 化学化合物類 | |
| JP2024505561A5 (https=) | ||
| ES2335026T3 (es) | Nuevo procedimiento de preparacion de lercanipidina. | |
| US6677483B2 (en) | Process for the production of monoamides of DTPA | |
| JPH11508567A (ja) | β−アミノ−α−ヒドロキシカルボン酸及びその誘導体の製造方法 | |
| TW503231B (en) | Method for preparing 3-aminot-1,2-propandiol derivatives |